Knee osteoarthritis (KOA) is a degenerative disease of knee cartilage caused by a variety of factors and secondary bone hyperplasia. The main clinical manifestations are knee pain, limited activity and deformity, etc. Some patients are accompanied by joint swelling and stiffness, which seriously affects their quality of life.
Conditions
Interventions
Treatment group:Umbilical cord blood mononuclear cells were injected into the articular cavity
Control group:Hyaluronic acid was injected into the joint cavity
Sponsors
Shandong Provincial Third Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1) 45-60 years old,with genders unlimited; 2) Diagnosed with primary knee osteoarthritis according to American College of Rheumatology criteria; 3) Patients with mild to moderate KOA (Kellgren-Lawrence grade III and below); 4) No knee surgery was performed in the first 6 months; 5) The blood sugar of patients with diabetes should be effectively controlled; 6)Understanding the research protocol and voluntarily signing the informed consent form;
Exclusion criteria
Exclusion criteria: 1) People with known or suspected allergic history, serious adverse reaction or allergic constitution to the cells used in the study; 2) Infectious arthritis or skin disease around the knee; 3) The knee has received drug injection treatment within 2 months; 4) Serious effusion of knee joint; 5) suffering from tumor disease; 6) Severe heart and lung dysfunction or abnormal liver and kidney function; 7) HBV, HCV, HIV and other active infections; 8) Participating in or currently participating in other clinical trials within one month before enrollment; 9) Patients deemed unsuitable for inclusion by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain Scale (VAS) Status;Western Ontario and Manchester University Osteoarthritis Index Visualization Scale (WOMAC)Status;Knee Injury and Osteoarthritis Outcome Score Status; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cytokine content in joint fluid Status;Joint fluid/plasma proteomics Status;Adverse event rate; | — |
Countries
China
Contacts
Public ContactHao wei
Shandong Provincial Third Hospital
Outcome results
None listed